The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 284-294
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagome, K.
Right arrow Articles by Yamamoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagome, K.
Right arrow Articles by Yamamoto, K.

IL-5-Induced Hypereosinophilia Suppresses the Antigen-Induced Immune Response via a TGF-beta-Dependent Mechanism1

Kazuyuki Nakagome*, Makoto Dohi2,*, Katsuhide Okunishi*, Ryoichi Tanaka*, Taku Kouro{dagger}, Mitsunobu R. Kano{ddagger}, Kohei Miyazono{ddagger}, Jun-ichi Miyazaki§, Kiyoshi Takatsu{dagger} and Kazuhiko Yamamoto*

* Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; {dagger} Division of Immunology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; {ddagger} Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; and § Division of Stem Cell Regulation Research, Osaka University Graduate School of Medicine, Osaka, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Although eosinophils play an essential role in allergic inflammation, their role has recently been under controversy. Epidemic studies suggest that hypereosinophilia induced by parasite infection could suppress subsequent Ag sensitization, although the mechanism has not been fully clarified. In this study, we investigated whether eosinophils could suppress the Ag-specific immune response in the airway. BALB/c mice were sensitized and airway challenged with OVA. Systemic hypereosinophilia was induced by delivery of an IL-5-producing plasmid. IL-5 gene delivery suppressed the Ag-specific proliferation and cytokine production of CD4+ T cells in the spleen. IL-5 gene delivery before OVA sensitization significantly suppressed airway eosinophilia and hyperresponsiveness provoked by subsequent OVA airway challenge, while delivery during the OVA challenge did not suppress them. This IL-5-induced immune suppression was abolished in eosinophil-ablated mice, suggesting an essential role of eosinophils. IL-5 treatment increased the production of TGF-beta1 in the spleen, and we demonstrated that the main cellular source of TGF-beta1 production was eosinophils, using eosinophil-ablated mice and depletion study. TGF-beta1, but not IL-5 itself, suppressed the Ag-specific immune response of CD4+ T cells in vitro. Furthermore, IL-5 treatment enhanced phosphorylation of Smad2 in CD4+ T cells. Finally, a TGF-beta type I receptor kinase inhibitor restored this IL-5-induced immune suppression both in vitro and in vivo. These results suggest that IL-5-induced hypereosinophilia could suppress sensitization to Ag via a TGF-beta-dependent mechanism, thus suppressed allergic airway inflammation. Therefore, hypereosinophilia could reveal an immunosuppressive effect in the early stage of Ag-induced immune response.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Over the past several decades, the prevalence of allergic diseases such as bronchial asthma has increased in industrialized countries (1). Bronchial asthma is a chronic disorder characterized by eosinophilic airway inflammation, mucus hypersecretion, partly reversible airway obstruction, heightened airway hyperresponsiveness (AHR),3 and airway remodeling (2). Th2 cell-type immune responses play a critical role in the development of bronchial asthma.

Eosinophils are thought to be one of the principal inflammatory cells in the pathophysiology of asthma. They release various lipid mediators, cytokines, and growth factors involved in the pathogenesis of asthma (3, 4). In eosinophil-deficient PHIL mice, both mucus hypersecretion and AHR were abolished (5), although these findings were not confirmed in another eosinophil-ablated strain, {Delta}dbl GATA mice (6). In addition, several clinical studies found a close correlation between the number of blood or airway eosinophils and the intensity of AHR or airway remodeling in asthmatic patients (7, 8, 9, 10, 11). These findings strongly indicate that eosinophils play a central role in the effector phase of allergic inflammation.

In contrast, the role of eosinophils in allergic inflammation has recently come under great scrutiny. For example, administration of humanized IL-5-neutralizing mAb does not decrease AHR despite this treatment’s depletion of blood and sputum eosinophils (12), although another study demonstrated that administration of this neutralizing anti-IL-5 mAb does not completely exclude eosinophils from the lung (13). These results suggest that eosinophils may not be the only factor in the induction and maintenance of AHR. In addition, epidemic studies demonstrate that children infected with the helminth parasite present a diminished skin test reactivity to other Ags as well as a decreased risk of wheezing (14, 15, 16, 17, 18), although these findings remain controversial (19). In animal studies, a passive helminth infection before systemic OVA sensitization suppresses subsequent airway eosinophilia induced by OVA inhalation (20, 21). As parasite infections are generally accompanied by hypereosinophilia, these findings beg the question of whether eosinophils play a protective role in the Ag-induced immune response under certain circumstances. In a study by Kobayashi et al. (22), in IL-5 transgenic mice, AHR induced by Ag sensitization was reduced despite marked eosinophil infiltration in the airway. This finding supports our speculation that eosinophils might play a protective role. However, a precise mechanism was neither proposed nor investigated in their report, leaving the association between eosinophils and immune suppression unresolved to this day.

The purpose of the present study was to investigate whether eosinophils could suppress Ag-specific immune response in the airway and to clarify the mechanism of this suppression. We delivered IL-5 gene into mice to induce systemic eosinophilia, and then examined its effect on allergic airway inflammation. We found that hypereosinophilia induced during Ag sensitization suppressed subsequent airway eosinophilia and AHR provoked by Ag inhalation, whereas that induced during the effector phase did not. Furthermore, we found that TGF-beta1 produced by eosinophils in the spleen played a critical role.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Male BALB/c mice were obtained from Charles River Japan. OVA TCR-transgenic DO11.10 mice and {Delta}dbl GATA mice (6, 23) were obtained from The Jackson Laboratory. All animal experiments were approved by the Animal Research Ethics Board of the Department of Allergy and Rheumatology, University of Tokyo.

Delivery of IL-5 into mice

In this study, we delivered IL-5 in vivo using a hydrodynamic-based method through the i.v. injection of plasmid DNA from previously reported methods (24, 25, 26). The plasmid pCAGGS-IL-5 (27) was amplified in Escherichia coli, and purified with a Qiagen Endo Free plasmid Giga kit (Qiagen). The empty plasmid pCAGGS was used as a control. Plasmid DNA in lactated Ringer’s solution (0.1 ml/g body weight) was injected i.v. from the tail, and injection was completed within 5 s. Some mice received plasmid DNA (100 µg; pCAGGS-IL-5 or control pCAGGS) i.v. on day –3 (before systemic immunization: pre) or on day 17 (during aerosol challenge; after systemic immunization: post).

Immunization of mice and evaluation of allergic airway inflammation

Mice were immunized as reported previously (24, 28, 29). Seven-week-old animals were sensitized with an i.p. injection of 2 µg of OVA (Sigma-Aldrich) plus 2 mg of aluminum hydroxide (alum) on days 0 and 11. Control mice received injections of physiologic saline (SA) on days 0 and 11. Mice were challenged with an aerosolized solution of 3% OVA or PBS for 10 min from day 18 to day 20. On day 21, airway responsiveness (AR) to methacholine (Mch) was measured with the enhanced pause (Penh) system or assessed by measuring airway resistance (Raw) as described previously (24, 29). Mch concentration that induced a 100% increase in Penh or Raw was expressed as PC200Mch (µg/ml) or PC200Mch Raw (µg/ml) as an indicator of AHR. Samples of serum and bronchoalveolar lavage fluid (BALF) were then obtained. The lungs were cut out and fixed with 10% neutralized buffered formalin (Wako). Three-micrometer-thick sections were prepared and subjected to H&E or periodic acid-Schiff (PAS) staining to evaluate mucus hypersecretion.

Measurement of cytokines and Ig

IL-4, IL-5, IL-10, IL-13, IFN-{gamma}, TGF-beta1, cysteinyl leukotrienes (cysLTs), IgE, and IgG concentrations were measured using ELISA kits (IL-4, IL-5, IL-10, IFN-{gamma}, and IgE from BD Pharmingen; IL-13 and TGF-beta1 from R&D Systems; cysLTs from Cayman Chemical; and IgG from Bethyl Laboratories). OVA-specific IgE or IgG was measured using an ELISA kit for IgE or IgG, although the plate was coated with OVA (1000 µg/ml) at 4°C overnight instead of anti-mouse IgE or IgG Ab. The OVA-specific IgE or IgG standard was derived by pooling sera from five OVA-sensitized mice. Results are expressed as a percentage of the value of the standard.

Preparation of spleen cells

Spleen cells were prepared as reported previously (24). The number of total splenic cells and eosinophils was counted 1, 3, 5, 8, 12, 18, and 24 days after plasmid injection. To clearly distinguish eosinophils from the neutrophils, three different stains were applied: Diff-Quick stain, May-Grünwald-Giemsa stain, and Eosino (Hansel) stain (30). On the basis of the findings with these stainings, cell differentials were counted with at least 300 leukocytes in each sample. The cell types were judged according to standard hemocytologic procedures. We also confirmed the reliability of our manual eosinophil counts by flow cytometric analysis with anti-Siglec F mAb (31) (BD Pharmingen). For the preparation of splenic CD4+ T cells, spleen cells were incubated with anti-CD4 mAb-coated microbeads (Miltenyi Biotec). The bead-bound cells were then isolated using magnetic separation columns. The purities of the enriched CD4+ cell populations were 95% (data not shown). Splenic eosinophils or eosinophil-depleted cells were prepared using previously reported methods with a slight modification (32, 33, 34). Briefly, spleen cells were incubated with anti-Thy1 mAb-coated microbeads (Miltenyi Biotec), anti-B220 mAb-coated microbeads (Miltenyi Biotec), and biotinylated anti-MHC class II mAb (anti I-A/I-E mAb; 2G9; BD Pharmingen), all of which were then incubated with streptavidin-microbeads (Miltenyi Biotec). The bead-bound cells were isolated for eosinophil-depleted cells using magnetic separation columns. To obtain purified eosinophils, the bead-bound cells were depleted, and the depleted cells were incubated with PE anti-CCR3 mAb (R&D Systems) and were then incubated with PE-microbeads (Miltenyi Biotech). The bead-bound cells were isolated for eosinophils using magnetic separation columns. The purities of each subset were found to be greater than 94% according to the morphologic criteria.

In vitro proliferation and cytokine assays

Spleen cells were cultured (5 x 105 cells/well) with or without OVA (20 µg/ml) in complete DMEM. In some experiments, positively selected CD4+ T cells (2.5 x 105 cells/well) were cultured with freshly isolated mitomycin C (Sigma)-treated splenocytes (2.5 x 105 cells/well) and OVA (20 µg/ml). After 72 or 96 h, the proliferation was assessed with a cell proliferation ELISA BrdU kit (Roche Applied Science). After 120 h, cytokine concentrations in the supernatants were measured using ELISA kits. For measurement of TGF-beta1 concentrations, we used serum-free medium X-vivo 15 (Cambrex BioScience) instead of complete DMEM. We measured total TGF-beta1 concentrations after complete activation by acidification. In some experiments, positively selected CD4+ T cells (1.25 x 105 cells/well) were incubated in Ag-nonspecific manner with plate-bound anti-CD3 Ab (10 µg/ml; BD Pharmingen) for 48 h or PMA (1 ng/ml; Sigma-Aldrich) and ionomycin (1 µg/ml; Sigma-Aldrich) for 24 h, after which the proliferation was assessed. To examine the direct effect of TGF-beta1 or IL-5 on CD4+ T cell functions in vitro, OVA-sensitized CD4+ T cells (1.25 x 105 cells/well) were incubated with plate-bound anti-CD3 Ab (10 µg/ml) for 48 h or PMA (1 ng/ml) and ionomycin (1 µg/ml) for 24 h with TGF-beta1 (2 or 10 ng/ml; R&D Systems) or IL-5 (5 or 20 ng/ml; R&D Systems), after which the proliferation was assessed. To examine the effect of coincubation with TGF-beta1 or IL-5 on Ag-specific immune response of CD4+ T cells, OVA-sensitized CD4+ T cells (2.5 x 105 cells/well) were incubated with freshly isolated mitomycin C-treated splenocytes (2.5 x 105 cells/well) and OVA (20 µg/ml) for 72 h with TGF-beta1 (2 or 10 ng/ml) or IL-5 (5 or 20 ng/ml). The proliferation was then assessed and the IL-4 concentration measured.

Effect of anti-IL-5R mAb on Ag-specific immune response of CD4+ T cells

Mice were sensitized with OVA or SA on day 0 and received plasmid (pCAGGS-IL-5 or control pCAGGS) on day –3. Some pCAGGS-IL-5-injected mice received anti-IL-5R mAb (35) (H7; 1 mg) or control IgG i.p. on days –2, –1, and 1. On day 11, splenic CD4+ T cells were obtained and the proliferation was examined as described previously.

Immunohistochemistry

Spleens were directly frozen in dry-iced acetone. Frozen samples were further sectioned at 10-µm thickness in a cryostat, fixed with 10% formalin, and then incubated with primary and secondary Abs. Anti-phospho Smad2 Ab (a gift from A. Moustakas and C.-H. Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden)) and anti-CD4 Ab (2 µg/ml; Santa Cruz Biotechnology) were used as primary Abs. Alexa 488-conjugated anti-rabbit IgG Ab (Molecular Probes) and Alexa 594-conjugated anti-rat IgG Ab (Molecular Probes) were used as secondary Abs. Samples were observed using a Zeiss LSM510 Meta confocal microscope.

Eosinophil peroxidase (EPO) activity

EPO activity was measured in the cell-free supernatants using previously reported methods (36). Briefly, cell-free supernatants (75 µl) were transferred to a 96-well microplate, and the reaction was initiated by the addition of substrate solution (75 µl). The substrate solution consisted of 12 mM o-phenylenediamine (Sigma-Aldrich), 0.005% H2O2 (Wako), 10 mM HEPES, and 0.22% cetyltrimethylammonium bromide (CTAB; Sigma-Aldrich). The reaction was stopped with 50 µl of 4 N sulfuric acid, and absorbance was measured at 490 nm. As a positive control, eosinophil extract was obtained from lysed eosinophils using previously reported methods (37). Briefly, eosinophils were suspended in 10 mM HEPES buffer containing 0.22% CTAB. After vortexing for 1 min, the suspensions were freeze-thawed once, spun at 10,000 x g for 10 min, and the supernatant was used as eosinophil extract.

CFSE proliferation assay

CD4+ T cells obtained from DO11.10 mice were labeled with the mitosis-sensitive dye CFSE (2.5 µM; Molecular Probes). CFSE-labeled CD4+ T cells (1 x 106 cells/well) were incubated with mitomycin C-treated splenocytes from naive mice (1 x 106 cells/well) and OVA (20 µg/ml) in the presence or absence of eosinophils (1 x 106 cells/well). After 48 or 96 h, the cells were harvested from the well and stained with CyChrome anti-CD4 mAb (BD Pharmingen). Proliferation of CD4+ T cells was assessed for dilution of the CFSE label by flow cytometry.

Effect of TGF-beta type I receptor kinase inhibitor (TbetaR-I inhibitor) on Ag-specific immune response of CD4+ T cells and Ag-induced eosinophilic airway inflammation

Mice were sensitized with OVA or SA on day 0 and received plasmid (pCAGGS-IL-5 or control pCAGGS) on day –3. Some plasmid-injected mice (pCAGGS-IL-5 or control pCAGGS) received TbetaR-I inhibitor ([3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole; 20 µg; Calbiochem (catalog no. 616451)) or DMSO i.p. on days –1, 1, 3 6, 8, and 10. On day 11, splenic CD4+ T cells were obtained, and the proliferation was examined as described previously. To examine the effect of TbetaR-I inhibitor on eosinophilic airway inflammation, mice were sensitized with OVA or SA on days 0 and 11 and received plasmid on day –3. Some plasmid-injected mice received TbetaR-I inhibitor or DMSO i.p. on days –1, 1, 3, 6, 8, 10, 13, 15, and 17. The mice were then challenged with OVA or PBS from day 18 to day 20. On day 21, the mice were analyzed.

Statistics

Values are expressed as means ± SEM. Statistical analysis was performed by one-way ANOVA followed, when differences were significant, by appropriate post hoc tests using Turkey-Kramer test. For analysis of the differences between two groups, we used Student’s t test. Values of p < 0.05 were considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
IL-5 expression in serum and in BALF after hydrodynamic-based gene delivery of plasmid DNA by i.v. injection

To induce systemic hypereosinophilia, we delivered the IL-5 gene by i.v. injecting the plasmid DNA (24, 25, 26). First, we examined the kinetics of IL-5. Samples were collected at predetermined time intervals following the injection of IL-5-expressing plasmid (pCAGGS-IL-5) or control plasmid (control pCAGGS). The temporal expression of the IL-5 protein in serum (Fig. 1A) and in BALF (Fig. 1B) was confirmed. The level of IL-5 peaked 1 day after the injection, and gradually decreased thereafter.


Figure 1
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 1. Expression of IL-5 and number of splenic eosinophils after a hydrodynamic-based gene delivery of plasmid DNA via i.v. injection. Mice received an i.v. injection of pCAGGS-IL-5 (IL-5) or control pCAGGS (CONT) on day 0. A and B, Concentrations of IL-5 in serum (A) and in BALF (B) were measured at the indicated times postinjection using ELISA. Values are presented as means ± SEM for six mice per group. C, Total spleen cell count after plasmid injection. D, Number of splenic eosinophils after plasmid injection. *, p < 0.05, **, p < 0.01, and ***, p < 0.001 compared with the value of CONT.

 
In vivo IL-5 gene delivery increases the number of splenic eosinophils

Next, we examined the kinetics of the number of total cells as well as eosinophils in the spleen after plasmid injection. Injection of pCAGGS-IL-5 (p-IL-5) induced an increase in the number of total splenic cells and eosinophils, whereas injection of control pCAGGS (p-Cont) did not (Fig. 1, C and D). On day 3, the number of splenic eosinophils had already increased significantly in the pCAGGS-IL-5-injected mice (p-IL-5 mice) (Fig. 1D). On day 11, number of total splenic cells from p-IL-5 mice was 6-fold greater than that of control pCAGGS-injected mice (p-Cont mice) or naive mice. Over 60% of splenocytes in the p-IL-5 mice were eosinophils at this point. We also confirmed the reliability of our manual eosinophil counts by flow cytometric analysis with anti-Siglec F mAb (31) (data not shown).

In vivo IL-5 gene delivery before systemic Ag sensitization suppresses Ag-induced eosinophilic airway inflammation, mucus hypersecretion, and AHR

We next elucidated the effect of IL-5 gene delivery on Th2-mediated allergic inflammation using an experimental model of allergic airway inflammation (Fig. 2). Mice were sensitized with either OVA or SA, and then challenged with nebulized OVA or PBS. Injection of plasmid (p-IL-5 or p-Cont) was performed before the systemic Ag sensitization (Pre, on day –3) or during the aerosol challenge (after systemic Ag sensitization; Post, on day 17). In vivo IL-5 delivery alone (with SA i.p. injection) induced mild infiltration of eosinophils into BALF (Fig. 2A). OVA-sensitization and nebulization markedly increased eosinophils in BALF (Fig. 2A). IL-5 gene delivery before sensitization significantly diminished the infiltration of eosinophils (Fig. 2A). Histologically, in vivo IL-5 delivery alone induced moderate infiltration of eosinophils in the alveolar walls, whereas infiltration of eosinophils in peribronchial area was mild (Fig. 2B). These findings were consistent with those observed in the IL-5 transgenic mice (22). The histology of OVA-sensitized and OVA-challenged mice revealed a prominent infiltration of eosinophils into the peribronchial interstitial area and mucus hypersecretion by bronchial epithelial cells (Fig. 2B). In the mice that received p-IL-5 injection before sensitization (pre-p-IL-5 mice), infiltration of inflammatory cells in peribronchial area and mucus hypersecretion both decreased (Fig. 2, B and C). Although there was a moderate infiltration of eosinophils in the alveolar walls in the pre-p-IL-5 mice, the intensity was similar to the baseline level observed in the mice that received in vivo IL-5 delivery alone (Fig. 2, B and C). In contrast, IL-5 gene delivery during the aerosol challenge deteriorated the infiltration of eosinophils and mucus hypersecretion compared with mice that had received the p-Cont during the aerosol challenge (Fig. 2B). AHR to Mch decreased in the pre-p-IL-5 mice, as was measured by the Penh system (Fig. 2D) and by Raw (Fig. 2E). BALF IL-13 concentration also decreased in the pre-p-IL-5 mice, whereas IFN-{gamma} did not (Fig. 2F), suggesting that IL-5 gene delivery had suppressed the Th2-mediated immune response in the airway. IL-5 delivery before sensitization suppressed OVA-specific IgE and total IgE production (Fig. 2G and data not shown). It slightly suppressed OVA-specific IgG and total IgG production, although there was not significant (Fig. 2G and data not shown). These results indicate that in vivo IL-5 gene delivery during the initial stage of sensitization, but not during the effector phase, suppressed allergic airway inflammation.


Figure 2
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 2. In vivo IL-5 gene delivery before systemic sensitization (pre) suppresses eosinophilic airway inflammation, mucus hypersecretion, and AHR. Mice were sensitized with OVA or SA on days 0 and 11. Some mice received an i.v. injection of pCAGGS-IL-5 (IL-5) or control pCAGGS (CONT) on day –3 (pre) or on day 17 (post). The mice were nebulized with OVA or PBS from day 18 to day 20. On day 21, the mice were analyzed. A, In vivo IL-5 delivery before sensitization suppresses eosinophil count in BALF. BALF analyses were performed (n = 12). Leukocytes were identified by morphologic criteria. B, Histological findings. Lungs were excised and subjected to H&E staining. Scale bar, 200 µm. Insets, PAS staining. Scale bar, 40 µm. C, Histological findings (low power field, H&E staining). Lung sections from mice that received control pCAGGS before sensitization and from mice that received pCAGGS-IL-5 before sensitization were shown. Scale bar, 400 µm. D, In vivo IL-5 gene delivery before sensitization suppresses AHR. Airway responsiveness (AR) to Mch was measured with a Penh system (n = 12). E, AR was assessed by measuring Raw (n = 12). F, BALF cytokine concentrations. Supernatant of BALF was assayed for IL-13 and IFN-{gamma} concentrations by ELISA (n = 12). G, OVA-specific IgE and IgG concentrations. Blood samples were obtained from the mice. OVA-specific IgE and IgG concentrations were measured by ELISA (n = 12). Pooled sera from five OVA-sensitized mice were set as a control (OVA; 100%). *, p < 0.05, **, p < 0.01, and ***, p < 0.001 compared with the value of SA/PBS or SA. #, p < 0.05 compared with the value of CONT.

 
In vivo IL-5 gene delivery suppresses the Ag-induced immune response of CD4+ T cells ex vivo

Next, we examined the effect of in vivo IL-5 gene delivery on the Ag-induced immune response by conducting ex vivo analyses. Mice received either p-IL-5 or p-Cont before OVA sensitization. On day 11, whole spleen cells or CD4+ cells were subjected to analyses. In the p-IL-5 mice, the splenic cells showed a diminished proliferation (Fig. 3A) and cytokine production (Fig. 3B) in response to OVA compared with mice that had received OVA-sensitization without plasmid injection (OVA mice), or to p-Cont mice. As the physiological ratio of CD4+ T cells in the spleen had differed between p-IL-5-mice and p-Cont mice, we then examined the effect of IL-5 on purified CD4+ T cells, and found that similar results were obtained (Fig. 3, C and D). These results indicated that in vivo IL-5 gene delivery before sensitization suppressed the Ag-induced overall immune response of CD4+ T cells. Next, to examine whether the suppression would be Ag specific or not, purified CD4+ T cells were stimulated with anti-CD3 Ab or PMA/ionomycin. In the p-IL-5-mice, proliferation and cytokine production of CD4+ T cells were slightly suppressed, however, they were not significant (Fig. 3E). Therefore, IL-5 gene delivery suppressed immune response mainly by Ag-specific mechanism, although Ag-nonspecific mechanism for suppression might have existed.


Figure 3
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 3. In vivo IL-5 gene delivery suppresses the Ag-induced immune response of CD4+ T cells. Mice were sensitized with OVA or SA on day 0. Some mice received plasmid (pCAGGS-IL-5 or control pCAGGS) on day –3. On day 11, the mice were analyzed. A and B, Proliferation and cytokine production of whole spleen cells in response to OVA. Whole spleen cells (5 x 105 cells/well) were incubated with OVA (20 µg/ml). A, After 72 h, the proliferation was assessed based on BrdU incorporation (n = 6). The maximum proliferation observed in response to OVA for spleen cells from OVA-sensitized mice was set as a control (OVA; 100%). B, After 120 h, cytokine levels of the supernatants were measured (n = 6). C and D, Proliferation and cytokine production of CD4+ T cells in response to OVA. Splenic CD4+ T cells (2.5 x 105 cells/well) were positively selected by magnetic cell sorting and cultured with freshly isolated mitomycin C-treated splenocytes (2.5 x 105 cells/well) and OVA (20 µg/ml). C, After 96 h, the proliferation was assessed (n = 6). The maximum proliferation observed in response to OVA for splenic CD4+ T cells from OVA-sensitized mice was set as a control (OVA; 100%). D, After 120 h, cytokine levels of the supernatants were measured (n = 6). E, Proliferation of CD4+ T cells in response to plate-bound anti-CD3 Ab or PMA/ionomycin. Splenic CD4+ T cells (1.25 x 105 cells/well) were positively selected and incubated with plate-bound anti-CD3 Ab (10 µg/ml) for 48 h or PMA (1 ng/ml) and ionomycin (1 µg/ml) for 24 h. The proliferation was assessed (n = 6). The maximum proliferation observed in response to plate-bound anti-CD3 Ab or PMA/ionomycin for splenic CD4+ T cells from OVA-sensitized mice was set as a control (OVA; 100%). ***, p < 0.001 compared with the value of SA. ##, p < 0.01 and ###, p < 0.001 compared with the value of CONT.

 
Eosinophils and IL-5 protein play a critical role in the suppression of the immune response of CD4+ T cells induced by in vivo IL-5 gene delivery

Next, we examined whether eosinophils would play a critical role in the IL-5-induced immune suppression. To examine an essential role of eosinophils, we used the eosinophil-ablated mice ({Delta}dbl GATA mice) for analyses. IL-5 gene delivery did not increase the number of eosinophils in the spleen of the {Delta}dbl GATA mice (data not shown). In the {Delta}dbl GATA mice, suppression of Ag-induced immure response of CD4+ T cells by IL-5 gene delivery, observed in wild-type mice (Fig. 3, C and D), was completely abrogated (Fig. 4A). These results suggested that eosinophils played an essential role in the IL-5-induced immune suppression. We then confirmed that the effect of in vivo IL-5 gene delivery was indeed mediated by the IL-5 protein. In vivo IL-5 gene delivery suppressed the Ag-specific proliferation of CD4+ T cells in a plasmid dose-dependent manner (Fig. 4B). We also examined the effect of anti-IL-5R mAb. Administration of anti-IL-5R mAb decreased the number of eosinophils in the spleen of p-IL-5 mice to ~20% of the eosinophil count in the control IgG-treated mice (on day 11; 4.13 ± 0.32 x 106 (IL-5 gene delivery + control IgG); 0.78 ± 0.03 x 106 (IL-5 gene delivery + anti-IL-5R mAb)). This treatment restored the suppression of Ag-specific proliferation of CD4+ T cells induced by p-IL-5 injection (Fig. 4C). These results confirmed that the IL-5 protein itself played an essential role in triggering the hyporesponsiveness of CD4+ T cells induced by in vivo IL-5 gene delivery.


Figure 4
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 4. Eosinophils and IL-5 protein play a critical role in the suppression of CD4+ T cells induced by in vivo IL-5 gene delivery. A, Effect of deletion of eosinophils on the IL-5-induced immune suppression. Eosinophil-ablated {Delta}dbl GATA mice (GATAKO) received plasmid (pCAGGS-IL-5 or control pCAGGS; 100 µg) on day –3 and were sensitized with OVA or SA on day 0. On day 11, the proliferation of splenic CD4+ T cells was examined based on BrdU incorporation (n = 6). The maximum proliferation observed in response to OVA for splenic CD4+ T cells from OVA-sensitized {Delta}dbl GATA mice was set as a control (GATAKO/OVA; 100%). ***, p < 0.001 compared with the value of GATAKO/SA. B, Effect of dose of IL-5 plasmid on the proliferation of CD4+ T cells. Wild-type mice received plasmid (pCAGGS-IL-5; 0.01, 0.1, 1, 10, 100 µg, or control pCAGGS; 100 µg) on day –3 and were sensitized with OVA or SA on day 0. On day 11, the proliferation of splenic CD4+ T cells was examined based on BrdU incorporation (n = 6). The maximum proliferation observed in response to OVA for splenic CD4+ T cells from OVA-sensitized mice was set as a control (OVA; 100%). ***, p < 0.001 compared with the value of SA. ###, p < 0.001 compared with the value of CONT. C, Effect of anti-IL-5R mAb on the proliferation of CD4+ T cells. Wild-type mice received plasmid on day –3 and were sensitized with OVA or SA on day 0. Some pCAGGS-IL-5-injected mice received anti-IL-5R mAb (1 mg) or control IgG i.p. on days –2, –1, and 1. On day 11, the proliferation of splenic CD4+ T cells was examined based on BrdU incorporation (n = 6). ***, p < 0.001 compared with the value of SA. ##, p < 0.01 compared with the value of IL-5/Cont IgG.

 
In vivo IL-5 gene delivery up-regulates the production of TGF-beta1 from spleen cells

We speculated that IL-5 exhibited its immunosuppressive effect on CD4+ T cells indirectly, probably by affecting immunosuppressive cytokines. We then examined the production of IL-10 and TGF-beta1. IL-5 gene delivery did not induce IL-10 production in whole spleen cells (Fig. 5A). By contrast, it significantly up-regulated total amounts of TGF-beta1 production (Fig. 5B). We subsequently examined these cellular productions using CD4+ T cell. CD4+ T cells from p-IL-5 mice produced much less IL-10 compared with OVA mice or p-Cont mice (Fig. 5C). In contrast, TGF-beta1 production by CD4+ T cells in the p-IL-5 mice did not differ from that in the OVA mice nor from the p-Cont mice (Fig. 5D). In addition, in a preliminary study, the ratio of CD4+CD25+ cells to CD4+CD25– cells did not increase in the p-IL-5 mice (data not shown). Furthermore, although Foxp3 mRNA expression in CD4+ T cells was slightly up-regulated in the p-IL-5 mice, the CD4+ T cells did not manifest suppressive activity (data not shown). Therefore, IL-5 gene delivery would not induce regulatory T (Treg) cells in our system. These results suggested that TGF-beta1-producing cells other than CD4+ T cells might play a critical role in the suppression of OVA-induced immune response. As almost 60% of spleen cells were eosinophils at this point in time (Fig. 1), these results strongly suggested that eosinophils might be the main cellular sources of TGF-beta1 production.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 5. In vivo IL-5 gene delivery increases TGF-beta1 production from whole spleen cells, but not from CD4+ T cells. Mice were treated as described in Fig. 3. A and B, IL-10 or TGF-beta1 production of whole spleen cells in response to OVA. On day 11, whole spleen cells (5 x 105 cells/well) were incubated with OVA (20 µg/ml). After 120 h, the concentration of IL-10 (A) or TGF-beta1 (B) of the supernatants was assayed (n = 6). C and D, IL-10 or TGF-beta1 production of CD4+ T cells in response to OVA. On day 11, splenic CD4+ T cells (2.5 x 105 cells/well) were positively selected by magnetic cell sorting and cultured with freshly isolated mitomycin C-treated splenocytes (2.5 x 105 cells/well) and OVA (20 µg/ml). After 120 h, the concentration of IL-10 (C) or TGF-beta1 (D) of the supernatants was assayed (n = 6). *, p < 0.05 and ***, p < 0.001 compared with the value of SA. #, p < 0.05 and ###, p < 0.001 compared with the value of CONT.

 
In vivo IL-5 gene delivery increases spontaneous TGF-beta1 production from eosinophils in the spleen

Next, we examined TGF-beta1 production from spleen cells. There was a significant increase in TGF-beta1 production of p-IL-5 mice compared with p-Cont mice on day 3 (Fig. 6A). The production was higher on day 11 (data not shown). We also confirmed by immunohistochemistry that IL-5 treatment up-regulated TGF-beta1 expression in the spleen (data not shown). In contrast, in the eosinophil-ablated {Delta}dbl GATA mice, IL-5 gene delivery did not increase TGF-beta1 production from whole spleen cells (Fig. 6A), which suggested that increase in TGF-beta1 production was mainly achieved by eosinophils in our system. Next, to confirm the TGF-beta1 production by eosinophils, we separated eosinophils from whole spleen cell suspension. Eosinophils produced a significantly higher amount of TGF-beta1 than other cells both on days 3 and 11 (Fig. 6, B and C), supporting the finding above that eosinophils were the main cellular source of TGF-beta1.


Figure 6
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 6. In vivo IL-5 gene delivery increases spontaneous TGF-beta1 production from splenic eosinophils. A, In vivo IL-5 gene delivery increases spontaneous TGF-beta1 production from spleen cells in wild-type mice, but not in eosinophil-ablated mice. Wild-type mice (Wild) or eosinophil-ablated {Delta}dbl GATA mice (GATAKO) received plasmid (pCAGGS-IL-5 or control pCAGGS) on day 0. On day 3, whole spleen cells were obtained and spontaneous production of TGF-beta1 for 24 h from spleen cells (1 x 106 cells/well) was examined using ELISA (n = 6). *, p < 0.05 compared with the value of CONT. B and C, The major cellular source for TGF-beta1 is eosinophils in the IL-5-treated mice. Wild-type mice received plasmid (pCAGGS-IL-5 or control pCAGGS) on day 0. Splenic eosinophils (Eo) or eosinophil-depleted cells (Eo (–)) were obtained on day 3 (B) or on day 11 (C) as described in Materials and Methods. Spontaneous TGF-beta1 production for 24 h from each subset (1 x 106 cells/well, respectively) was examined using ELISA (n = 6). TGF-beta1 production by eosinophils was set as a control (100%). *, p < 0.05 compared with the value of Eo (–). D, EPO activity. EPO activity of the cell-free supernatants of each subset (1 x 106 cells/well) was measured as described in Materials and Methods (n = 6). As a positive control, eosinophil extract was obtained from lysed eosinophils (Eo lysate; 100%; 1 x 106 cells/well). E, IL-5 production by eosinophils. IL-5 production from each subset (1 x 106 cells/well) was examined using ELISA (n = 6). F, Eosinophils could suppress the Ag-specific immure response of CD4+ T cells in vitro. CD4+ T cells obtained from DO11.10 mice were labeled with CFSE, and then incubated with mitomycin C-treated splenocytes from naive mice in the presence or absence of eosinophils. After 48 h, proliferation of CD4+ T cells was assessed by flow cytometry. Representative figures were shown.

 
In vivo IL-5 gene delivery does not activate eosinophils

We next clarified the activation state of eosinophils from p-IL-5 mice. First, we analyzed the expression of CD69, one of the markers for eosinophil activation, but could not confirm up-regulation in eosinophils from p-IL-5 mice (data not shown). Then, we measured secretion of EPO. Eosinophils from p-IL-5 mice did not release EPO (Fig. 6D). These eosinophils did not release cysLTs either (data not shown). These results suggested that eosinophils from p-IL-5 mice were not activated. We also measured production of other cytokines than TGF-beta. Purified eosinophils obtained from p-IL-5 mice did not increase cytokine production such as IL-5 and IFN-{gamma} (Fig. 6E and data not shown).

Eosinophils could suppress the Ag-specific immure response of CD4+ T cells in vitro

Next, to examine a suppressive role of eosinophils, coculture of eosinophils with APCs and CD4+ T cells was performed. Proliferation of CD4+ T cells was assessed by CFSE staining. Addition of eosinophils in coculture suppressed Ag-specific proliferation of CD4+ T cells (Fig. 6F), although this suppressive effect was mild. These results suggested that eosinophils could directly suppress the Ag-specific immune response of CD4+ T cells in vitro.

TGF-beta1 suppresses the immune response of CD4+ T cell in vitro

Next, we examined whether TGF-beta1 or IL-5 could suppress the immune response in vitro. When OVA-sensitized splenic CD4+ T cells were stimulated with APCs and OVA, TGF-beta1 suppressed the proliferation of CD4+ T cells and IL-4 production (Fig. 7, A and B). When the cells were stimulated with plate-bound anti-CD3 Ab, TGF-beta1 again suppressed the CD4+ T cell proliferation and IL-4 production (Fig. 7, C and D). In contrast, IL-5 did not suppress the OVA Ag-specific immune response of CD4+ T cells directly (Fig. 7, E and F). When the cells were stimulated with plate-bound anti-CD3 Ab or PMA/ionomycin, IL-5 did not suppress this proliferation either (Fig. 7G). Therefore, TGF-beta1, but not IL-5, played an essential role in the immunosuppressive response of CD4+ T cells induced by in vivo IL-5 gene delivery. In another experiment, we examined whether supernatant of IL-5-induced eosinophils could suppress the proliferation of CD4+ T cells. It did not suppress the proliferation probably because most of TGF-beta1 in the supernatant was inactive (data not shown).


Figure 7
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 7. TGF-beta1, but not IL-5, suppresses the immune response of CD4+ T cells in vitro. A and B, Effect of TGF-beta1 on Ag-specific immune response of CD4+ T cells. OVA-sensitized splenic CD4+ T cells (2.5 x 105 cells/well) were incubated with freshly isolated mitomycin C-treated splenocytes (2.5 x 105 cells/well) and OVA (20 µg/ml) for 72 h with or without TGF-beta1 (2 or 10 ng/ml). A, The proliferation was assessed (n = 6). The proliferation of CD4+ T cells in response to OVA without TGF-beta was set as a control (100%). B, IL-4 concentration in the supernatants (n = 6). **, p < 0.01 and ***, p < 0.001 compared with the value without TGF-beta1. C and D, Direct effect of TGF-beta1 on CD4+ T cells. OVA-sensitized splenic CD4+ T cells (1.25 x 105 cells/well) were incubated with plate-bound anti-CD3 Ab (10 µg/ml) for 48 h with or without TGF-beta1 (2 or 10 ng/ml). C, The proliferation was assessed (n = 6). The proliferation of CD4+ T cells in response to plate-bound anti-CD3 Ab without TGF-beta was set as a control (100%). D, IL-4 concentration (n = 6). *, p < 0.05 compared with the value without TGF-beta1. E and F, Effect of IL-5 on Ag-specific immune response of CD4+ T cells. OVA-sensitized splenic CD4+ T cells were incubated with freshly isolated mitomycin C-treated splenocytes and OVA for 72 h with or without IL-5 (5 or 20 ng/ml). E, The proliferation was assessed (n = 6). The proliferation of CD4+ T cells in response to OVA without IL-5 was set as a control (100%). F, IL-4 concentration (n = 6). G, Direct effect of IL-5 on CD4+ T cells. OVA-sensitized splenic CD4+ T cells were incubated with plate-bound anti-CD3 Ab for 48 h or PMA and ionomycin for 24 h with or without IL-5 (5 or 20 ng/ml). The proliferation was assessed (n = 6). The proliferation of CD4+ T cells in response to plate-bound anti CD3-Ab or PMA/ionomycin without IL-5 was set as a control (100%).

 
IL-5 gene delivery actually up-regulates TGF-beta signaling of CD4+ T cells

Next, we examined whether TGF-beta signaling was actually transduced in CD4+ T cells of p-IL-5 mice. We analyzed the phosphorylation status of Smad2, a downstream effecter for TGF-beta and an indicator of active TGF-beta signaling, in CD4+ T cells. Phosphorylated Smad2 expression in CD4+ T cells of the spleen strongly increased in the p-IL-5 mice as compared with that in the p-Cont mice (Fig. 8A), which suggested that IL-5 gene delivery up-regulated TGF-beta signaling of CD4+ T cells.


Figure 8
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 8. TGF-beta plays an important role in the suppression of CD4+ T cell-mediated immune response and the suppression of eosinophilic airway inflammation. A, IL-5 gene delivery up-regulated TGF-beta signaling of CD4+ T cells. Mice received plasmid (pCAGGS-IL-5 or control pCAGGS) on day –3 and were sensitized with OVA on day 0. On day 11, spleens were excised, and stained with anti-phospho Smad2 Ab (green) and anti-CD4 Ab (red). Double-positive cells indicated up-regulated TGF-beta signaling in CD4+ T cells. Scale bar, 10 µm. B, Effect of TbetaR-I inhibitor on Ag-specific proliferation of CD4+ T cells. Mice received plasmid (pCAGGS-IL-5 or control pCAGGS) on day –3 and were sensitized with OVA or SA on day 0. Some plasmid-injected mice (pCAGGS-IL-5 or control pCAGGS) received TbetaR-I inhibitor (20 µg) or DMSO i.p. on days –1, 1, 3 6, 8, and 10. On day 11, the proliferation of splenic CD4+ T cells was examined based on BrdU incorporation (n = 6). The maximum proliferation observed in response to OVA for splenic CD4+ T cells from OVA-sensitized mice was set as a control (OVA; 100%). C, Effect of TbetaR-I inhibitor on eosinophilic airway inflammation. Mice received plasmid on day –3 and were sensitized with OVA or SA on days 0 and 11. Some plasmid-injected mice received TbetaR-I inhibitor (20 µg) or DMSO i.p. on days –1, 1, 3, 6, 8, 10, 13, 15, and 17. The mice were then challenged with OVA or PBS from day 18 to day 20. On day 21, the mice were sacrificed. BALF analyses were performed (n = 12). D, BALF cytokine concentrations. Supernatant of BALF was assayed for IL-13 and IFN-{gamma} concentrations by ELISA (n = 12). E, OVA-specific IgE concentration. OVA-specific IgE concentration was measured by ELISA (n = 12). Pooled sera from five OVA-sensitized mice were set as a control (OVA; 100%). *, p < 0.05, **, p < 0.01, and ***, p < 0.001 compared with the value of SA. #, p < 0.05 and ##, p < 0.01 compared with the value of IL-5/DMSO.

 
TGF-beta plays an important role in the suppression of CD4+ T cell-mediated immune response and the suppression of eosinophilic airway inflammation

Finally, we examined the effect of TbetaR-I inhibitor on the IL-5-induced immune suppression. In the p-Cont mice, administration of TbetaR-I inhibitor did not affect the immune response of CD4+ T cells (Fig. 8B). CD4+ T cells from p-IL-5 mice proliferated in response to OVA when treated with the TbetaR-I inhibitor (Fig. 8B). Furthermore, administration of the TbetaR-I inhibitor restored the IL-5-induced suppression of eosinophilic airway inflammation although it did not affect the inflammation in the p-Cont-mice (Fig. 8C). It also restored the suppression of other Th2-mediated immune response such as IL-13 production in BALF (Fig. 8D) and OVA-specific IgE production in serum (Fig. 8E). These results strongly indicated that in vivo IL-5 gene delivery suppressed Ag-induced immune response of CD4+ T cells and eosinophilic airway inflammation through a TGF-beta-dependent mechanism.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study, we have demonstrated that eosinophils could suppress the Ag-specific immune response via a TGF-beta-dependent mechanism. Hypereosinophilia induced by in vivo IL-5 gene delivery before systemic sensitization suppressed the Ag-specific proliferation of CD4+ T cells in the spleen, eosinophilic airway inflammation, and AHR. IL-5 gene delivery increased TGF-beta production by spleen cells and the TGF-beta actually worked on CD4+ T cells. Eosinophils were the main cellular source of TGF-beta1 produced in the spleen. TbetaR-I inhibitor abolished this IL-5-induced immune suppression.

A study by Kobayashi et al. (22) demonstrated that in IL-5 transgenic mice, AHR induced by Ag sensitization was reduced despite a marked eosinophil infiltration in the airway. They also found an increase in TGF-beta1 in the lung in these mice. Treating the mice with IL-5 Ab diminished airway eosinophilia and TGF-beta1 whereas AHR increased. They therefore speculated that TGF-beta might have played an important role as an immunosuppressive cytokine in the suppression of AHR. However, in their report, airway inflammation was neither suppressed nor its mechanism elucidated. By contrast, in the current study, hypereosinophilia induced during sensitization inhibited both airway eosinophilia and AHR. We have clarified that suppression of AHR was achieved by suppressing Ag sensitization and the consequent airway inflammation. Furthermore, we found that TGF-beta1, which was mainly produced by eosinophils, played a key role in this suppression. A reason for the discrepancy in the results would be due to a difference in the expression of IL-5 protein (e.g., 2–40 µg/ml in our study (Fig. 1) vs 2–20 ng/ml in transgenic mice (38)). The finding that a lower dose of IL-5-expressing plasmid could not have suppressed the proliferation of CD4+ T cells (Fig. 4B; 0.01–1 µg) would support our speculation.

IL-5 is a cytokine that induces eosinophil proliferation, differentiation, and migration from bone marrow (39, 40, 41). It is generally considered an aggravating factor in the Ag-induced eosinophilic airway inflammation (42, 43, 44, 45, 46). However, in the current study, we demonstrated that in vivo IL-5 gene delivery before sensitization suppressed eosinophilic airway inflammation (Fig. 2) and the Ag-specific proliferation of CD4+ T cells (Fig. 3). Administration of anti-IL-5R mAb restored the suppression of the Ag-specific proliferation of CD4+ T cells induced by IL-5 gene delivery (Fig. 4C). These results suggested that in our system, IL-5 suppressed the Ag-specific proliferation of CD4+ T cells, thus suppressing eosinophilic airway inflammation. In contrast, it is known that T cells rarely express the IL-5R (39). We also confirmed through in vitro studies that IL-5 neither suppressed the Ag-specific immune response of CD4+ T cells nor did it directly suppress the proliferation of CD4+ T cells (Fig. 7). We believe that IL-5 contributed indirectly to the immunosuppressive response. We then extended our research to examine the expression of immunosuppressive cytokines, and found that TGF-beta1, and not IL-10, played a pivotal role.

TGF-beta is an immunosuppressive cytokine (47, 48). Generally, it suppresses the proliferation of CD4+ T cells and also blocks the differentiation of Th1 and Th2 cells (47, 48, 49, 50). In this study, TGF-beta1 suppressed the proliferation and cytokine production of CD4+ T cells in vitro (Fig. 7). In addition, in vivo IL-5 gene delivery increased OVA-induced TGF-beta1 production by spleen cells (Fig. 5B), and spontaneous TGF-beta1 production by spleen cells showed ~2-fold increase (Fig. 6A). Moreover, phosphorylated Smad2 expression in CD4+ T cells of the spleen strongly increased in the IL-5-treated mice (Fig. 8A), suggesting that IL-5 gene delivery up-regulated TGF-beta signaling of CD4+ T cells. Furthermore, TbetaR-I inhibitor restored the suppression of the proliferation of CD4+ T cells of IL-5-treated mice (Fig. 8B). Taken together, TGF-beta1 worked to suppresses the immune response in our system as well. Some reports have indicated that TGF-beta converts CD4+CD25– T cells to Treg cells in vitro though the induction of Foxp3 (51, 52). So it is likely that in vivo IL-5 gene delivery could have induced Treg cells in our system. However, our preliminary experiments suggested that Treg cells would not be induced by our IL-5 gene delivery. Instead, in our experimental system, TGF-beta1 could well have suppressed the overall Ag-induced immune response of CD4+ T cells.

Generally, eosinophils produce TGF-beta1 (9, 10, 11, 53, 54, 55). In this study, in vivo IL-5 gene delivery induced a marked increase in the number of splenic eosinophils (Fig. 1). In the eosinophil-ablated mice, IL-5 gene delivery did not suppress the Ag-induced immure response of CD4+ T cells (Fig. 4A). Although IL-5 treatment increased TGF-beta1 production by spleen cells in wild-type mice, it did not increase TGF-beta1 production in eosinophil-ablated {Delta}dbl GATA mice (Fig. 6A), which suggested that TGF-beta1 was mainly produced by eosinophils in our system. We also confirmed by depletion study that the main cellular source producing TGF-beta1 in the spleen were eosinophils (Fig. 6, B and C). Moreover, CFSE analyses suggested that eosinophils could suppress Ag-specific proliferation of CD4+ T cells in vitro (Fig. 6F), although the suppressive effect was mild. Therefore, in our system, TGF-beta1-producing eosinophils, induced by IL-5 gene delivery, played a central role in regulating the immune response of CD4+ T cells. An in vitro study demonstrating that IL-5 increased TGF-beta1 production from eosinophils (22) supports our speculation.

In this study, we demonstrated that eosinophils from IL-5-treated mice were not activated. Eosinophils from IL-5-treated mice did not express CD69, one of the markers for eosinophil activation (data not shown). Moreover, these eosinophils did not release eosinophil granule protein such as EPO (Fig. 6D). They did not release cysLTs either (data not shown). It is well known that mouse eosinophils do not routinely degranulate in vivo under any known circumstances (22, 56, 57, 58). Moreover, Lee et al. (56) recently suggested the possibility that eosinophil granule proteins might be an evolutionary vestige and they might not have effector function. So, in the current study, eosinophils would have produced TGF-beta1 without being activated or degranulated.

Recently, many epidemic studies have indicated that parasite infections inducing eosinophilia suppressed further sensitization to other Ags (14, 15, 16, 17, 18). Serum IL-5 concentration is higher in patients infected with parasites than in healthy subjects (59). Moreover, in animal studies, helminth infection before systemic OVA sensitization suppressed Ag-induced eosinophilic airway inflammation, whereas helminth infection after sensitization did not (20, 21). These findings are both similar to and in support of our current results obtained by IL-5 gene delivery. So far, one of the major mechanisms for suppression by parasite infection is considered the induction of parasite-mediating Treg cells (14, 15). In this study, we propose another mechanism where eosinophils, induced by parasite infection, might play an important role in the suppression of Th2 immune response through TGF-beta.

In summary, IL-5 gene delivery increased the TGF-beta1 production from spleen cells, thus suppressing the Ag-specific immune response of CD4+ T cells and Ag-induced eosinophilic airway inflammation. The major cellular source of TGF-beta1 in the IL-5 delivered mice was eosinophils, suggesting an important role of TGF-beta1-producing eosinophils in the early stage of Ag-specific immune response. This mechanism of immunosuppression would play a specific role in a possible suppression of asthma in instances such as parasite infection.


   Acknowledgments
 
We thank I. Makino and K. Kurosaki for their technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a grant-in-aid from the Ministry of Health, Welfare, and Labor of Japan (13670592). Back

2 Address correspondence and reprint requests to Dr. Makoto Dohi, Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. E-mail address: mdohi-tky{at}umin.ac.jp Back

3 Abbreviations used in this paper: AHR, airway hyperresponsiveness; alum, aluminum hydroxide; SA, physiologic saline; AR, airway responsiveness; Mch, methacholine; Penh, enhanced pause; Raw, airway resistance; BALF, bronchoalveolar lavage fluid; PAS, periodic acid-Schiff; cysLT, cysteinyl leukotriene; EPO, eosinophil peroxidase; CTAB, cetyltrimethylammonium bromide; TbetaR-I inhibitor, TGF-beta type I receptor kinase inhibitor; Treg, regulatory T. Back

Received for publication July 31, 2006. Accepted for publication April 24, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Bach, J. F.. 2002. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347: 911-920. [Free Full Text]
  2. Bochner, B. S., B. J. Undem, L. M. Lichtenstein. 1994. Immunological aspects of allergic asthma. Annu. Rev. Immunol. 12: 295-335. [Medline]
  3. Sanderson, C. J.. 1992. Interleukin-5, eosinophils, and disease. Blood 79: 3101-3109. [Free Full Text]
  4. Rothenberg, M. E.. 1998. Eosinophilia. N. Engl. J. Med. 338: 1592-1594. [Free Full Text]
  5. Lee, J. J., D. Dimina, M. P. Macias, S. I. Ochkur, M. P. McGarry, K. R. O’Neill, C. Protheroe, R. Pero, T. Nguyen, S. A. Cormier, et al 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773-1776. [Abstract/Free Full Text]
  6. Humbles, A. A., C. M. Lloyd, S. J. McMillan, D. S. Friend, G. Xanthou, E. E. McKenna, S. Ghiran, N. P. Gerard, C. Yu, S. H. Orkin, C. Gerard. 2004. A critical role for eosinophils in allergic airways remodeling. Science 305: 1776-1779. [Abstract/Free Full Text]
  7. Bousquet, J., P. Chanez, J. Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, P. Godard, F. B. Michel. 1990. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323: 1033-1039. [Abstract]
  8. Griffin, E., L. Hakansson, H. Formgren, K. Jorgensen, C. Peterson, P. Venge. 1991. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J. Allergy Clin. Immunol. 87: 548-557. [Medline]
  9. Ohno, I., Y. Nitta, K. Yamauchi, H. Hoshi, M. Honma, K. Woolley, P. O’Byrne, G. Tamura, M. Jordana, K. Shirato. 1996. Transforming growth factor beta1 (TGF beta1) gene expression by eosinophils in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol. 15: 404-409. [Abstract]
  10. Minshall, E. M., D. Y. Leung, R. J. Martin, Y. L. Song, L. Cameron, P. Ernst, Q. Hamid. 1997. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 17: 326-333. [Abstract/Free Full Text]
  11. Kay, A. B., S. Phipps, D. S. Robinson. 2004. A role for eosinophils in airway remodelling in asthma. Trends Immunol. 25: 477-482. [Medline]
  12. Leckie, M. J., A. ten Brinke, J. Khan, Z. Diamant, B. J. O’Connor, C. M. Walls, A. K. Mathur, H. C. Cowley, K. F. Chung, R. Djukanovic, et al 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148. [Medline]
  13. Flood-Page, P. T., A. N. Menzies-Gow, A. B. Kay, D. S. Robinson. 2003. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167: 199-204. [Abstract/Free Full Text]
  14. Yazdanbakhsh, M., P. G. Kremsner, R. van Ree. 2002. Allergy, parasites, and the hygiene hypothesis. Science 296: 490-494. [Abstract/Free Full Text]
  15. Maizels, R. M., M. Yazdanbakhsh. 2003. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat. Rev. Immunol. 3: 733-744. [Medline]
  16. van den Biggelaar, A. H., R. van Ree, L. C. Rodrigues, B. Lell, A. M. Deelder, P. G. Kremsner, M. Yazdanbakhsh. 2000. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 356: 1723-1727. [Medline]
  17. Scrivener, S., H. Yemaneberhan, M. Zebenigus, D. Tilahun, S. Girma, S. Ali, P. McElroy, A. Custovic, A. Woodcock, D. Pritchard, et al 2001. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. Lancet 358: 1493-1499. [Medline]
  18. Cooper, P. J., M. E. Chico, L. C. Rodrigues, M. Ordonez, D. Strachan, G. E. Griffin, T. B. Nutman. 2003. Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics. J. Allergy Clin. Immunol. 111: 995-1000. [Medline]
  19. Palmer, L. J., J. C. Celedon, S. T. Weiss, B. Wang, Z. Fang, X. Xu. 2002. Ascaris lumbricoides infection is associated with increased risk of childhood asthma and atopy in rural China. Am. J. Respir. Crit. Care Med. 165: 1489-1493. [Abstract/Free Full Text]
  20. Wang, C. C., T. J. Nolan, G. A. Schad, D. Abraham. 2001. Infection of mice with the helminth Strongyloides stercoralis suppresses pulmonary allergic responses to ovalbumin. Clin. Exp. Allergy 31: 495-503. [Medline]
  21. Wohlleben, G., C. Trujillo, J. Muller, Y. Ritze, S. Grunewald, U. Tatsch, K. J. Erb. 2004. Helminth infection modulates the development of allergen-induced airway inflammation. Int. Immunol. 16: 585-596. [Abstract/Free Full Text]
  22. Kobayashi, T., K. Iijima, H. Kita. 2003. Marked airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J. Immunol. 170: 5756-5763. [Abstract/Free Full Text]
  23. Yu, C., A. B. Cantor, H. Yang, C. Browne, R. A. Wells, Y. Fujiwara, S. H. Orkin. 2002. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J. Exp. Med. 195: 1387-1395. [Abstract/Free Full Text]
  24. Nakagome, K., M. Dohi, K. Okunishi, Y. Komagata, K. Nagatani, R. Tanaka, J. Miyazaki, K. Yamamoto. 2005. In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J. Immunol. 174: 6955-6966. [Abstract/Free Full Text]
  25. Jiang, J., E. Yamato, J. Miyazaki. 2001. Intravenous delivery of naked plasmid DNA for in vivo cytokine expression. Biochem. Biophys. Res. Commun. 289: 1088-1092. [Medline]
  26. Liu, D., J. E. Knapp. 2001. Hydrodynamics-based gene delivery. Curr. Opin. Mol. Ther. 3: 192-197. [Medline]
  27. Tokui, M., I. Takei, F. Tashiro, A. Shimada, A. Kasuga, M. Ishii, T. Ishii, K. Takatsu, T. Saruta, J. Miyazaki. 1997. Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5. Biochem. Biophys. Res. Commun. 233: 527-531. [Medline]
  28. Okunishi, K., M. Dohi, K. Nakagome, R. Tanaka, K. Yamamoto. 2004. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J. Immunol. 173: 6393-6402. [Abstract/Free Full Text]
  29. Nakagome, K., M. Dohi, K. Okunishi, Y. To, A. Sato, Y. Komagata, K. Nagatani, R. Tanaka, K. Yamamoto. 2005. Antigen-sensitized CD4+CD62Llow memory/effector T helper 2 cells can induce airway hyperresponsiveness in an antigen free setting. Respir. Res. 6: 46[Medline]
  30. Dohi, M., S. Tsukamoto, T. Nagahori, K. Shinagawa, K. Saitoh, Y. Tanaka, S. Kobayashi, R. Tanaka, Y. To, K. Yamamoto. 1999. Noninvasive system for evaluating the allergen-specific airway response in a murine model of asthma. Lab. Invest. 79: 1559-1571. [Medline]
  31. Zhang, J. Q., B. Biedermann, L. Nitschke, P. R. Crocker. 2004. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol. 34: 1175-1184. [Medline]
  32. Woerly, G., K. Honda, M. Loyens, J. P. Papin, J. Auwerx, B. Staels, M. Capron, D. Dombrowicz. 2003. Peroxisome proliferator-activated receptors {alpha} and {gamma} down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198: 411-421. [Abstract/Free Full Text]
  33. Oliveira, S. H., D. D. Taub, J. Nagel, R. Smith, C. M. Hogaboam, A. Berlin, N. W. Lukacs. 2002. Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis. Blood 100: 4291-4297. [Abstract/Free Full Text]
  34. Shen, H. H., S. I. Ochkur, M. P. McGarry, J. R. Crosby, E. M. Hines, M. T. Borchers, H. Wang, T. L. Biechelle, K. R. O’Neill, T. L. Ansay, et al 2003. A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J. Immunol. 170: 3296-3305. [Abstract/Free Full Text]
  35. Hitoshi, Y., N. Yamaguchi, M. Korenaga, S. Mita, A. Tominaga, K. Takatsu. 1991. In vivo administration of antibody to murine IL-5 receptor inhibits eosinophilia of IL-5 transgenic mice. Int. Immunol. 3: 135-139. [Abstract/Free Full Text]
  36. Clark, K., L. Simson, N. Newcombe, A. M. Koskinen, J. Mattes, N. A. Lee, J. J. Lee, L. A. Dent, K. I. Matthaei, P. S. Foster. 2004. Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen. J. Leukocyte Biol. 75: 1001-1009. [Abstract/Free Full Text]
  37. Schneider, T., A. C. Issekutz. 1996. Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase: application in a Brown Norway rat model of allergic pulmonary inflammation. J. Immunol. Methods 198: 1-14. [Medline]
  38. Tominaga, A., S. Takaki, N. Koyama, S. Katoh, R. Matsumoto, M. Migita, Y. Hitoshi, Y. Hosoya, S. Yamauchi, Y. Kanai, et al 1991. Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production. J. Exp. Med. 173: 429-437. [Abstract/Free Full Text]
  39. Takatsu, K.. 1992. Interleukin-5. Curr. Opin. Immunol. 4: 299-306. [Medline]
  40. Clutterbuck, E. J., E. M. Hirst, C. J. Sanderson. 1989. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73: 1504-1512. [Abstract/Free Full Text]
  41. Lopez, A. F., C. J. Sanderson, J. R. Gamble, H. D. Campbell, I. G. Young, M. A. Vadas. 1988. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med. 167: 219-224. [Abstract/Free Full Text]
  42. Iwamoto, T., K. Takatsu. 1995. Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Int. Arch. Allergy Immunol. 108: (Suppl. 1):28-30. [Medline]
  43. Tanaka, H., N. Kawada, T. Yamada, K. Kawada, K. Takatsu, H. Nagai. 2000. Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor {alpha} chain-deficient mice. Clin. Exp. Allergy 30: 874-881. [Medline]
  44. Hamelmann, E., A. Oshiba, J. Loader, G. L. Larsen, G. Gleich, J. Lee, E. W. Gelfand. 1997. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am. J. Respir. Crit. Care Med. 155: 819-825. [Abstract]
  45. Foster, P. S., S. P. Hogan, A. J. Ramsay, K. I. Matthaei, I. G. Young. 1996. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183: 195-201. [Abstract/Free Full Text]
  46. Lee, J. J., M. P. McGarry, S. C. Farmer, K. L. Denzler, K. A. Larson, P. E. Carrigan, I. E. Brenneise, M. A. Horton, A. Haczku, E. W. Gelfand, et al 1997. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J. Exp. Med. 185: 2143-2156. [Abstract/Free Full Text]
  47. Gorelik, L., R. A. Flavell. 2002. Transforming growth factor beta in T cell biology. Nat. Rev. Immunol. 2: 46-53. [Medline]
  48. Levings, M. K., R. Bacchetta, U. Schulz, M. G. Roncarolo. 2002. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129: 263-276. [Medline]
  49. Sad, S., T. R. Mosmann. 1994. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J. Immunol. 153: 3514-3522. [Abstract]
  50. Gorelik, L., P. E. Fields, R. A. Flavell. 2000. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165: 4773-4777. [Abstract/Free Full Text]
  51. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, S. M. Wahl. 2003. Conversion of peripheral CD4+CD25– naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886. [Abstract/Free Full Text]
  52. Fantini, M. C., C. Becker, G. Monteleone, F. Pallone, P. R. Galle, M. F. Neurath. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25– T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149-5153. [Abstract/Free Full Text]
  53. Ohno, I., R. G. Lea, K. C. Flanders, D. A. Clark, D. Banwatt, J. Dolovich, J. Denburg, C. B. Harley, J. Gauldie, M. Jordana. 1992. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta1 gene (TGF beta1). J. Clin. Invest. 89: 1662-1668. [Medline]
  54. Phipps, S., S. Ying, A. Wangoo, Y. E. Ong, F. Levi-Schaffer, A. B. Kay. 2002. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J. Immunol. 169: 4604-4612. [Abstract/Free Full Text]
  55. Elovic, A. E., H. Ohyama, A. Sauty, J. McBride, T. Tsuji, M. Nagai, P. F. Weller, D. T. Wong. 1998. IL-4-dependent regulation of TGF-{alpha} and TGF-beta1 expression in human eosinophils. J. Immunol. 160: 6121-6127. [Abstract/Free Full Text]
  56. Lee, J. J., N. A. Lee. 2005. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function?. Clin. Exp. Allergy 35: 986-994. [Medline]
  57. Adamko, D., S. O. Odemuyiwa, R. Moqbel. 2003. The eosinophil as a therapeutic target in asthma: beginning of the end, or end of the beginning?. Curr. Opin. Pharmacol. 3: 227-232. [Medline]
  58. Dombrowicz, D., M. Capron. 2001. Eosinophils, allergy and parasites. Curr. Opin. Immunol. 13: 716-720. [Medline]
  59. Malla, N., B. A. Fomda, M. A. Thokar. 2005. Serum cytokine levels in human ascariasis and toxocariasis. Parasitol. Res. 28: 1-4. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. Nakagome, K. Okunishi, M. Imamura, H. Harada, T. Matsumoto, R. Tanaka, J.-i. Miyazaki, K. Yamamoto, and M. Dohi
IFN-{gamma} Attenuates Antigen-Induced Overall Immune Response in the Airway As a Th1-Type Immune Regulatory Cytokine
J. Immunol., July 1, 2009; 183(1): 209 - 220.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Bower, O. Veraitch, R. Szydlo, P. Charles, P. Kelleher, B. Gazzard, M. Nelson, and J. Stebbing
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease
Blood, May 7, 2009; 113(19): 4521 - 4524.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagome, K.
Right arrow Articles by Yamamoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagome, K.
Right arrow Articles by Yamamoto, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS